Streetbeat News

Price Targets

DE

Wells Fargo analyst Seth Weber maintains an Overweight rating on Deere (NYSE:DE) but lowers the price target from $510 to $490.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:39 am

KNX

Citigroup analyst Christian Wetherbee upgrades Knight-Swift (NYSE:KNX) from Neutral to Buy and raises the price target from $58 to $66.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:37 am

TBI

BMO Capital analyst Jeffrey Silber upgrades TrueBlue (NYSE:TBI) from Market Perform to Outperform and raises the price target from $18 to $20.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:36 am

FL

Barclays analyst Adrienne Yih maintains an Equal-Weight rating on Foot Locker (NYSE:FL) and lowers the price target from $42 to $31.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:35 am

AZUL

Bank of America Securities analyst Murilo Freiberger upgraded Azul (NYSE:AZUL) from Underperform to Neutral and raised the price target from $6.9 to $11.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:35 am

NSC

Wells Fargo analyst Allison Poliniak upgrades Norfolk Southern (NYSE:NSC) from Equal-Weight to Overweight and raises the price target from $225 to $250.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:33 am

CTLT

JP Morgan analyst Tycho Peterson downgraded Catalent (NYSE:CTLT) from Overweight to Neutral and lowered the price target from $90 to $45.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:23 am

SKWD

JMP Securities analyst Matthew Carletti maintains a Market Outperform rating on Skyward Specialty (NASDAQ:SKWD) and raises the price target from $26 to $28.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:20 am

PYPL

Bernstein analyst Harshita Rawat maintains a Market Perform rating on PayPal Holdings (NASDAQ:PYPL) and lowers the price target from $85 to $70.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 10:19 am

MIRM

HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $61 price target.

Portfolio Pulse from richadhand@benzinga.com

May 22, 2023 | 10:18 am